CO2022009561A2 - Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 - Google Patents

Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4

Info

Publication number
CO2022009561A2
CO2022009561A2 CONC2022/0009561A CO2022009561A CO2022009561A2 CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2 CO 2022009561 A CO2022009561 A CO 2022009561A CO 2022009561 A2 CO2022009561 A2 CO 2022009561A2
Authority
CO
Colombia
Prior art keywords
melanocortin
treatment methods
disorders associated
receptor pathway
receptor
Prior art date
Application number
CONC2022/0009561A
Other languages
English (en)
Inventor
Der Ploeg Leonardus H T Van
Alastair Garfield
Bhavik P Shah
Original Assignee
Rhythm Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhythm Pharmaceuticals Inc filed Critical Rhythm Pharmaceuticals Inc
Publication of CO2022009561A2 publication Critical patent/CO2022009561A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

La divulgación está relacionada con un método de tratamiento de un trastorno, un desorden o una condición asociados con un gen agonizable de la vía MC4R, como la obesidad o la hiperfagia, en un sujeto usando un agonista del receptor de melanocortina-4 (MC4R).
CONC2022/0009561A 2020-09-24 2022-07-07 Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4 CO2022009561A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063082867P 2020-09-24 2020-09-24
PCT/US2021/052032 WO2022067086A1 (en) 2020-09-24 2021-09-24 Methods of treating melanocortin-4 receptor pathway-associated disorders

Publications (1)

Publication Number Publication Date
CO2022009561A2 true CO2022009561A2 (es) 2022-07-19

Family

ID=80845850

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0009561A CO2022009561A2 (es) 2020-09-24 2022-07-07 Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4

Country Status (13)

Country Link
US (1) US20240058414A1 (es)
EP (1) EP4216979A1 (es)
JP (1) JP2023542985A (es)
KR (1) KR20230095956A (es)
CN (1) CN116507353A (es)
AR (1) AR123603A1 (es)
AU (1) AU2021350017A1 (es)
CA (1) CA3192873A1 (es)
CL (1) CL2023000823A1 (es)
CO (1) CO2022009561A2 (es)
MX (1) MX2023003360A (es)
TW (1) TW202228760A (es)
WO (1) WO2022067086A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024015880A2 (en) * 2022-07-12 2024-01-18 Rhythm Pharmaceuticals, Inc. Methods for treating obesity with an mc4r agonist

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101257916B (zh) * 2005-07-08 2013-04-03 益普生制药股份有限公司 黑皮质素受体配体
CN108601816A (zh) * 2015-09-30 2018-09-28 节奏制药公司 治疗黑皮质素-4受体路径相关联病症的方法

Also Published As

Publication number Publication date
AR123603A1 (es) 2022-12-21
CL2023000823A1 (es) 2023-09-15
WO2022067086A1 (en) 2022-03-31
CA3192873A1 (en) 2022-03-31
KR20230095956A (ko) 2023-06-29
TW202228760A (zh) 2022-08-01
EP4216979A1 (en) 2023-08-02
AU2021350017A1 (en) 2023-05-04
CN116507353A (zh) 2023-07-28
JP2023542985A (ja) 2023-10-12
US20240058414A1 (en) 2024-02-22
MX2023003360A (es) 2023-06-23

Similar Documents

Publication Publication Date Title
MX2022010425A (es) Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
EA201992474A2 (ru) Агонисты 5ht для лечения нарушений
CO2022009561A2 (es) Métodos de tratamiento de los trastornos asociados a la vía del receptor de melanocortina 4
UY37269A (es) Agonista del receptor de glucocorticoides e inmunoconjugados del mismo
CO2021005231A2 (es) Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha)
EA201000673A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ИЗМЕРЕНИЯ АКТИВАЦИИ Wnt И ДЛЯ ЛЕЧЕНИЯ Wnt-ОПОСРЕДОВАННЫХ РАКОВЫХ ЗАБОЛЕВАНИЙ
PH12017502120A1 (en) A method and an apparatus for forming a lignin fraction, a lignin composition and its use
EA201792437A1 (ru) Способы и композиции для лечения нарушений, ассоциированных со старением
CL2018003565A1 (es) Anticuerpos antifactor de la coagulación xi.
CL2022001256A1 (es) Métodos y composiciones para tratar un trastorno asociado con el angiotensinogeno agt
CO2020005417A2 (es) Inhibidores de la quinasa p38 que reducen la expresión de dux4 y de los genes corriente abajo para el tratamiento de fshd
CR20160132A (es) Composiciones y método para tratar condiciones asociadas con el complemento
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
BR112018006674A2 (pt) método de tratamento de distúrbios associados com a via do receptor de melanocortina-4
CO2021008998A2 (es) Amidas de pirrolidina iii sustituidas
MX2022008320A (es) Métodos para tratar trastornos de pénfigo.
CL2021001903A1 (es) Tratamiento de la hepatotoxicidad
WO2018150276A3 (en) The combination of cotinine plus antioxidant for treatment resistant depression and other neuropathological conditions
EA201891253A1 (ru) Способ получения высококачественного исходного материала для процесса парового крекинга
CL2020002165A1 (es) Uso de tradipitant para tratar la cinetosis.
WO2023086428A3 (en) Novel modulators of the aryl hydrocarbon receptor and methods of use thereof
CU20200038A7 (es) Compuestos derivados de pirazolo-pirrolo-pirimidina-diona como inhibidores de p2x3
MX2023005342A (es) Métodos para tratar padecimientos relacionados con el receptor s1p1.
CL2023003126A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa
MX2022012302A (es) Formas polimórficas de metopimazina novedosas.